Summary Primary prevention with aminoguanidinean inhibitor of advanced glycation end product (AGE) formation -has been successfully employed to prevent diabetic retinopathy in the rat. However, it is unknown whether inhibition of AGE formation is still effective in a secondary intervention strategy. The present study addresses this question by comparing secondary intervention with aminoguanidine with syngeneic islet transplantation in the rat model. After 6 months of diabetes, one group was treated with aminoguanidine (50 mg/100ml drinking water; D-AG) while another group received syngeneic transplantation of collagenase-ficoll isolated islets by intraportal injection (Tx). After an additional 4 months, both groups were compared to a normal (NC 10) and diabetic (DC 10) control group. Retinal autofluorescence was increased 2.5-fold after 6 months and increased 3.7-fold after 10 months of diabetes (p < 0.001). Aminoguanidine and islet Tx retarded the further accumulation of autofluorescence equally (p < 0.001 vs DC 10), although the values were higher than those observed in DC at 6 months (p < 0.001). Diabetes was associated with a 2.7-fold increase in acellular capillaries after 6 months and a 4.1-fold increase after 10 months. Treatment with aminoguanidine or islet Tx reduced but did not completely attenuate the progression of vascular occlusion (p < 0.001 vs DC 10; D-AG vs DC 6, p < 0.05; Tx vs DC 6, p < 0.01). Both treatments reduced endothelial proliferation (22.4% after 10months; p < 0.001) and completely arrested pericyte dropout (40 % after 10 months;p < 0.001).
development of proliferations in 60 % of IDDM patients [3] which is the major cause of blindness in the adult population of western countries [4] . Experimental and clinical studies have demonstrated the causal relationship between the cumulative history of glycaemia and the development of retinopathy [5, 6] . Animal studies using aminoguanidine -an inhibitor of hyperglycaemia-derived advanced glycation end product (AGE) formation -have shown that experimental diabetic retinopathy can be prevented by the inhibition of AGE formation [7, 8] . However, it is not known whether aminoguanidine would be effective in a secondary strategy. We studied this question in an established rat model of experimental diabetic retinopathy in comparison to secondary res-toration of near-normoglycaemia by islet transplantation, and found secondary treatment with aminoguanidine to be as effective as islet transplantation in retarding the progression of experimental diabetic retinopathy.
Materials and methods
Animals. Male Lewis rats (Han.Lew, Zentralinstitut fur Versuchstierkunde, Hannover, Germany) weighing 200-250 g at the outset were used in this experiment. Diabetes was induced by i. v. injection of streptozotocin (STZ, 65 mg/kg body weight; Boehringer Mannheim, Mannheim, Germany). Only animals with blood glucose exceeding 15 mmol/1 at 1 week after STZinjection were included into the diabetic groups. All rats were fed a regular laboratory rodent chow (Altromin, Lage, Germany) ad libitum and had free access to drinking water.
Blood glucose (glucose oxidase method) and body weight were monitored at regular intervals. After 6 months of constant hyperglycaemia, animals were randomly assigned to receive either 50 rag/100 ml drinking water aminoguandine-HCL (Riedel-de Haen, Hannover, Germany) (D-AG) or intraportal islet transplantation (Tx) (see below) or no treatment (DC). A non-diabetic (NC 6) and diabetic (DC 6) group were killed and the eyes removed for examination. Water consumption was identical in the aminoguanidine-treated and the untreated diabetic group.
Glycated haemoglobin (Glyc Affin GHb, Isolab, DRG, Marburg, Germany) was measured in each group at the time of killing.
Islet transplantation. Islet transplantation was performed using the method of Lacy and Kostianovsky [9] . Briefly, the donor pancreas (non-diabetic Lewis rat) was digested with 10 ml collagenase (0.02 %) via the ductus choledochus, separated from the surrounding small gut and incubated for 45 rain at 37 ~ Before centrifugation (30 rain, 900 g) against a Ficoll gradient (Sigma, Heidelberg, Germany), the digest was homogenized by whirling on a vortex for 15 s and washed twice in ice-cold Hanks' solution (Gibco, Eckenstein, Germany). A total of approximately 1000 freshly isolated islets was given intraportally in the anaesthesized animal.
After 10 months (i.e. after 4 months of treatment), untreated diabetic rats (DC t0), their age-matched non-diabetic counterparts (NC 10) and diabetic rats treated with aminoguanidine (D-AG) or islet transplantation (Tx) were killed.
The time course of the study is given in Figure 1 .
Retinal digest preparations. Retinae were obtained at the time points indicated above after enucleation of the eyes from the animals under deep anaesthesia and immediately fixed in 4 % buffered formalin.
Retinal vascular preparations were performed using a pepsin-trypsin digestion technique as previously described [7, 10] . Briefly, a combined pe, psin (5 % pepsin in 0.2 % hydrochloric acid for 1.5 h) trypsin (2.5 % in 0.2 tool/1 Tris for 15-30 rain) digestion was used to isolate the retinal vasculature and the specimens were stained with periodic acid Schiff. Retinal autofluorescence was measured in unstained digest preparations according to a previously published method [7, 8] .
Acellular capillaries were quantitated by a modification of the method of Engerman and Kern [11] . Using a grid of 100 fields, 10 microscopic fields covering a total area of 6.76 mm 2 of retinal area were scored for the presence of acellular occluded vessels (integration ocular Olympus/400 • ). Each field con- Months Fig. 1 . Schematic of the study design. Non-diabetic (C523) and diabetic rats (11) were killed after 6 and 10 months respectively. Treatments with aminoguanidine (D-AG) and islet transplantation (Islet Tx) were started after 6 months of diabetes (m) and continued for 4 months (~) taining acellular capillary segments was recorded as positive, and values were normalized to mm 2 of retinal area. The total number of endothelial cells and pericytes (average approximately 170 cells per retina) was counted in 10 randomly selected fields of the retina using an image analysing system (CUE 2; Olympus Opt. Inc., Hamburg, Germany). Differentiation of pericytes from endothelial cells was performed according to the criteria of Kuwabara and Cogan [10] . Pericyte identification was facilitated using a polyclonal anti-vitronectin antibody (rb 69, kindly provided by Klaus Preissner, Max-Planck-Institut, Bad Nauheim, Germany). The numbers of each cell type were normalized to the relative capillary density (numbers of cells per mm 2 of capillary area).
One retina per animal was used for morphometric evaluation. Morphometry was performed with the identity of the samples remaining unknown.
Statistical analysis
All parameters are given as mean _+ SD unless otherwise stated. One-way analysis of variance was performed, followed by Bonferroni-t-tests to correct for multiple comparisons and assign differences to individual groups where overall significance (p < 0.05) was attained.
Results
STZ-induced diabetes resulted in stable hyperglycaemia ( Fig. 2) and progressive weight loss as well as in an almost threefold increase in Amadori product formation ( Table 1 ). Aminoguanidine that was given from month 6 to month 10 (D-AG) did not alter the level of Amadori products (HbA1). Plasma aminoguanidine levels were 18.64 + 2.98 ~tg/ml in the D-AG group. Islet transplantation, performed after 6 months of diabetes, was accompanied by significantly improved glucose and Amadori product levels (blood glucose and HbA 1 Tx vs DC 10 p < 0.001, re- , non-diabetic after 6 months; NC 10, non-diabetic after 10 months; DC 6, diabetic after 6 months; DC 10, diabetic after 10 months; D-AG, diabetic rats, treated with aminoguanidine; Tx, diabetic rats, treated with islet transplantation. Results are shown as mean + SD. "p < 0.001 vs NC 6; bp < 0.001 VS NC 10; ~p < 0.01 vs NC 10; dp < 0.001 VS DC 10; ep < 0.05 vs NC 10. Differences of HbA~ between DC 6, DC 10 and D-AG were not significant. Plasma aminoguanidine concentrations were measured according to the method of Beaven et al. [12] Increased retinal vascular autofluorescence was predominantly observed at the branching sites of precapillary arterioles of diabetic animals and, to some extent, in treated diabetic rats (Fig. 3) . The location was identical to those published previously [7] .
Autofluorescence quantitation revealed an almost 2.5-fold increase of fluorescent AGEs in DC 6 and a further rise after 10 months of untreated diabetes. (Fig.4) .
Retinae from diabetic rats showed a 2.7-fold increase in acellular capillaries after 6 months and a 4.1 fold increase after 10 months compared to agematched NC (DC 6 vs NC 6 and DC 10 vs NC 10 p < 0.001). Both forms of treatment significantly reduced the progression of acellular capillaries to the same degree (D-AG 64.4 + 9.6 (mean + SEM) and Tx 71 + 3.9 vs DC 10 101 + 7.5; p < 0.001 for each comparison; D-AG vs DC 6 51 + 2.1; p < 0.05; Tx vs DC 6 p < 0.01) (Fig. 5) .
Determined exclusively in areas where capillary occlusions or severe irregularities were absent, chronic hyperglycaemia induced a 17.6 % increase in endothelial cell numbers after 6 months (DC 6 2505 + 123 cells/ram 2 of capillary area vs NC 6 2130_+99; 
Discussion
The results from this study indicate that secondary inhibition of AGE-accumulation can retard but not arrest the progression of diabetic retinopathy in the rat model to the same degree as syngeneic islet transplantation. Concomitantly, both treatment forms were shown to retard but not arrest further accumulation of AGEs as indicated by the difference of the treated groups with the untreated diabetic group (DC 10). These data are consistent with a causal role for AGEs in the pathogenesis of diabetic retinopathy [13] , and suggest that other hyperglycaemia-induced mechanisms [14] inhibited by islet Tx may be less important 9 The mechanism by which aminoguanidine and islet Tx exert the beneficial effect on the retinal microvasculature appears to be by lowering the levels of AGEs [15] or their reactive precursors [16] either directly (aminoguanidine) or indirectly through the reconstitution of near-normoglycaemia (islet Tx). Our 659 study also confirms that AGEs that have formed cannot be removed by secondary inhibition 9 Continued progression of diabetic retinopathy after correction of hyperglycaemia or inhibition of AGE formation is consistent with previous descriptions of hyperglycaemic memory [11, 17] . While the biochemical basis has not been elucidated, it is consistent with persistent damage by preformed AGEs.
Similar data of secondary aminoguanidine treatment in diabetic nephropathy have recently been reported by Soulis-Liparota et al. [18] . In their experimental design, rats were untreated for 16 weeks and treated for the same time period in comparison to normal and diabetic controls. Urinary albumin excretion was intermediate between the normal and the untreated diabetic group. In contrast to our findings, diabetes-related increase in glomerular and tubular fluorescence was completely prevented in the treated group. The measurement of autofluorescence grossly underestimates the total amounts of AGEs formed, at least in the kidney, since the majority of AGEs is non-fluorescent [19] . Therefore, non-fluorescent AGEs could have contributed to the incomplete suppression of albuminuria in these animals 9 Several other properties of aminoguanidine have been described to explain its beneficial effects on diabetic vascular complications such as the inhibition of the polyol pathway or the correction of the vascular flow by acting as an inhibitor of the inducible form of the nitric oxide synthase (iNOS) [20, 21] . However, at concentrations used in our study, aminoguanidine does not have inhibitory effects on the polyol pathway or the iNOS.
In conclusion, secondary intervention of experimental diabetic retinopathy by AGE inhibition is likely to have a beneficial effect on disease progression. Concomitant retardation of retinal autofluorescence and capillary occlusions, accompanied by a preventive effect on pericyte loss, equally obtained by aminoguanidine and syngeneic islet transplantation, provides further insight into the pathogenesis of diabetic retinopathy. These data provide the basis for investigating the effect of aminoguanidine in a secondary intervention trial in patients 9
